Vaxart

VXRT Micro Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$0.61

+0% today

52W: $0.26 – $0.84

52W Low: $0.26 Position: 60.3% 52W High: $0.84

🔗 Compare Brokers

Key Metrics

P/E Ratio

8.71x

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

0.62x

Price-to-Sales

EV/EBITDA

3.6x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$147.3M

Market Capitalization

Revenue Growth

586.5%

YoY Revenue Growth

Profit Margin

6.88%

Net profit margin

ROE

22.26%

Return on Equity

Beta

1.32

Market sensitivity

Short Interest

9.4%

% of float sold short

Avg. Volume

819,021

Average daily volume

Valuation Analysis

Signal

Undervalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

None

2 analysts

Avg. Price Target

$3.00

+391.8% upside

Target Range

$2.00 – $4.00

About the Company

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with A

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 65 Exchange: OQX